Viatris Inc. Monday reported a loss for the fourth quarter and all of 2021, unveiled another restructuring and announced an agreement to pay $264 million to settle a class-action lawsuit involving its EpiPen emergency allergy treatment.
The pharmaceuticals giant — which was formed through the merger of Mylan and Upjohn in November 2020 — said the first step in the restructuring was an agreement to sell its biosimilars portfolio to India-based Biocon Biologics for up to $3.335 billion. The deal includes $2 billion in cash, $1 billion in preferred shares for a stake in Biocon of at least 12.9% and up to $335 million in additional cash payments expected in 2024. Viatris has had a collaboration agreement with Biocon to develop, manufacture and commercialize biosimilar drugs for over a decade.
The transaction, which needs regulatory approval, is expected to be completed in the second half of this year. Biocon is planning an initial public offering in India in as early as the fourth quarter of 2023, Viatris said.
The restructuring — which comes on the heels of another restructuring in 2021 that included shuttering Mylan’s 56-year-old flagship generic drug plant in Morgantown, W.Va. in July — is intended to remake Viatris into a “simpler, stronger and more focused” company, CEO Michael Goettler told analysts in a conference call Monday morning.
Besides the Biocon transaction, the restructuring is expected to generate an additional $6 billion in pre-tax proceeds by the end of 2023 through the sale of non-core assets. The company isn’t disclosing which assets would be put up for sale.
Mr. Goettler told analysts that “2022 and 2023 are years of execution … to set ourselves up for success in 2024 and beyond.”
Read More
He said Viatris, based in Cecil, would seek to expand its holdings in three main areas: ophthalmology, dermatology and gastrointestinal products.
The company also announced that its board of directors authorized a share repurchase program worth up to $1 billion.
Viatris’ stock skidded 24.3% Monday, losing $3.53 per share to close at $11.01.
The company said it had agreed to pay $264 million to settle a class action alleging it was involved in a scheme to delay generic competition to maintain a monopoly for the EpiPen.
Viatris said it acted lawfully and that the settlement does not include any admission of liability.
The case was brought on behalf of consumers and third-party payers such as insurers, following widespread backlash in 2016 against Mylan for raising the price of the Epipen by some 500% — from about $100 for a two-pack in 2007 when Mylan acquired the product to just over $600, making it unaffordable for many uninsured consumers or people with high-deductible plans.
In 2017, Mylan paid $465 million in a settlement with the U.S. Justice Department for overcharging Medicaid for the EpiPen. And in 2019, it paid $30 million to settle with the U.S. Securities and Exchange Commission over charges that it made “false and misleading” public filings concerning the EpiPen.
On Monday, Viatris reported a loss of $263.8 million for the fourth quarter compared with a loss of $915.8 million in the same quarter a year earlier.
Sales rose 21% to $4.33 billion from $3.59 billion.
For all of 2021, the company lost $1.27 billion vs. a loss of $669.9 billion in 2020.
Sales rose 51% to $17.81 billion from $11.82 billion.
Patricia Sabatini: PSabanii@post-gazette.com; 412-263-3066.
This story was updated at 4:35 p.m. on Feb. 28 with the closing stock price.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.